Bausch Health Companies Inc. (BHC)
NYSE: BHC · IEX Real-Time Price · USD
7.60
+0.22 (2.98%)
At close: Jul 19, 2024, 4:00 PM
7.61
+0.01 (0.13%)
After-hours: Jul 20, 2024, 12:56 PM EDT
Bausch Health Companies Employees
Bausch Health Companies had 20,270 employees as of December 31, 2023. The number of employees increased by 370 or 1.86% compared to the previous year.
Employees
20,270
Change (1Y)
370
Growth (1Y)
1.86%
Revenue / Employee
$442,329
Profits / Employee
-$22,447
Market Cap
2.79B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 20,270 | 370 | 1.86% |
Dec 31, 2022 | 19,900 | 300 | 1.53% |
Dec 31, 2021 | 19,600 | -2,000 | -9.26% |
Dec 31, 2020 | 21,600 | -100 | -0.46% |
Dec 31, 2019 | 21,700 | 600 | 2.84% |
Dec 31, 2018 | 21,100 | 400 | 1.93% |
Dec 31, 2017 | 20,700 | -800 | -3.72% |
Dec 31, 2016 | 21,500 | -500 | -2.27% |
Dec 31, 2015 | 22,000 | 5,200 | 30.95% |
Dec 31, 2014 | 16,800 | -400 | -2.33% |
Dec 31, 2013 | 17,200 | 10,200 | 145.71% |
Dec 31, 2012 | 7,000 | 100 | 1.45% |
Dec 31, 2011 | 6,900 | 2,600 | 60.47% |
Dec 31, 2010 | 4,300 | 3,009 | 233.08% |
Dec 31, 2009 | 1,291 | -77 | -5.63% |
Dec 31, 2008 | 1,368 | -165 | -10.76% |
Dec 31, 2007 | 1,533 | -201 | -11.59% |
Dec 31, 2006 | 1,734 | -10 | -0.57% |
Dec 31, 2005 | 1,744 | -547 | -23.88% |
Dec 31, 2004 | 2,291 | 333 | 17.01% |
Dec 31, 2003 | 1,958 | 101 | 5.44% |
Dec 31, 2002 | 1,857 | 535 | 40.47% |
Dec 31, 2001 | 1,322 | 122 | 10.17% |
Dec 31, 2000 | 1,200 | 497 | 70.70% |
Feb 28, 1999 | 703 | 238 | 51.18% |
Dec 31, 1998 | 465 | 164 | 54.49% |
Jan 1, 1997 | 301 | 6 | 2.03% |
Jun 10, 1996 | 295 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
Tandem Diabetes Care | 2,400 |
Progyny | 566 |
MorphoSys AG | 524 |
Agios Pharmaceuticals | 386 |
SpringWorks Therapeutics | 227 |
Kymera Therapeutics | 187 |
Geron | 141 |
Morphic Holding | 121 |
BHC News
- 3 days ago - Bausch Health Welcomes Two New Members to the Executive Leadership Team - Accesswire
- 10 days ago - Bausch + Lomb Will Release Second-Quarter 2024 Financial Results on July 31 - Business Wire
- 11 days ago - Bausch Health to Announce Second Quarter 2024 Results on August 1, 2024 - Accesswire
- 4 weeks ago - Bausch Health Brings Patent Infringement Lawsuit Against Norwich Pharmaceuticals - Accesswire
- 5 weeks ago - Bausch Health Reports Promising R&D Trial Updates on Amiselimod and Scientific Data Presented at International Healthcare Conferences - Accesswire
- 2 months ago - Salix to Present Late-Breaking Data from Phase 2 Trial of Amiselimod in Active Ulcerative Colitis at Digestive Disease Week 2024 - Accesswire
- 2 months ago - Bausch Health Announces 2024 Annual Meeting of Shareholder Results - Accesswire
- 2 months ago - Bausch Health Announces Updates Related to Norwich XIFAXAN Matters - Accesswire